tbuckley/cabot-search huggingface dataset:
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma
Authors: Jonathan Kantor
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Coronary Bypass Surgery — An ART for Dedicated Surgeons
Authors: Stuart J. Head, Arie P. Kappetein
Journal: New England Journal of Medicine (2019)

Coronary-artery bypass grafting (CABG), introduced in the 1960s, remains the standard revascularization treatment for complex coronary disease.1 The left internal thoracic artery, with its excellent patency when used as a graft, is the conduit of choice for anastomosis to the left anterior descending coronary artery. However, the selection of the second conduit remains a matter of debate. Most CABG procedures are performed with a left internal-thoracic-artery graft and saphenous-vein grafts, despite guidelines advocating the use of more arterial grafts. In particular, the use of bilateral internal-thoracic-artery grafting has been associated with better long-term survival than single internal-thoracic-artery grafting in observational . . .
Evaluating Proper Inhaler Technique in Children with Moderate-to-Severe Asthma
Authors: Alexandria Bozen, Jesse A. Blumenstock, Madeleine K. Kanaley, Kathy L. Boon, Jolanta W. Szkodon, Pamela J. Newmark, Avneet S. Chadha, Kristin Kan, Deneen Vojta, Ruchi S. Gupta
Journal: Journal of Allergy and Clinical Immunology (2019)
Lifestyle changes may be more important than drugs for mild hypertension
Authors: Rob Cook, Tara Lamont, Rosie Martin,
Journal: BMJ (2019)

The studySheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs R, McManus R. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension.Published on 1 December 2018 JAMA Intern Med 2018;178:1626-34.This project was funded by a grant from the National Institute for Health Research (NIHR-RP-R2-12-O15) and the Medical Research Council (MRC) Strategic Skills Postdoctoral Fellowship.To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000713/lifestyle-changes-for-mild-hypertension-rather-than-drugs.
TCT-515 Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 6-month Results from the DESolve PMCF Study
Authors: Holger Nef, Karl-Eugen Hauptmann, Azeem Latib, Ricardo A. Costa, Lynn Morrison, Sara Toyloy, Lynn Vandertie, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
Long-term outcomes of surgical resection of lung metastases from colorectal cancer.
Authors: Ryota Mori, Yoshinori Kagawa, Yoshiro Yukawa, Keisuke Toya, Kouki Takase, Yohei Nose, Kenji Kawai, Takuya Sakamoto, Atsushi Naito, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Toru Masuzawa, Atsushi Takeno, Yutaka Takeda, Takeshi Kato, Aya Yamamoto, Michihito Toda, Takashi Iwata, Kohei Murata
Journal: Journal of Clinical Oncology (2019)

655 Background: The lungs are one of the most frequent sites of metastases from colorectal cancer(CRC). Surgical resection has been widely performed on patients with pulmonary metastases from CRC with favorable outcomes. Surgical treatment is considered an effective option, but the surgical indications of lung resection have institutional bias. In our hospital, we aggressively perform surgery for lung metastases when the primary tumor and other metastases are controlled and all lung metastases are resectable. In this study, the aim is to investigate the long-term outcomes of resections of lung metastases from CRC in our institute. Methods: Between April 2009 and November 2017, patients who underwent lung resections for metastases from CRC with curative intent in our hospital were investigated retrospectively. Kaplan-Meier survival curves, log-rank tests, chi-squared test and T-test were used to analyze the survival rates and the factors predicting recurrence. Results: Sixty-seven patients underwent lung resection of metastases from CRC. The median follow-up period was 25.3 (6-60) months. Five-year disease free survival was 33.6 % and 5-year overall survival was 63.9%. Because of pulmonary recurrence, second surgery was performed in 16 patients and a third surgery in three patients. 5-year overall survival rate after first lung resection in patients who underwent repeated lung resection was 49.2%. There was no significant difference between the number of patients with pulmonary recurrence and those with no recurrence after lung resection (p = 0.38). Twenty-one patients had experienced prior liver resection; the 5-year overall survival rate after lung resection in these patients was 57.9 %. Factors predicting recurrence were vascular invasion (v ≥ 2) of primary tumor (p = 0.02), pre-operative serum CEA (p = 0.03) and CA-19-9 (p = 0.04). Conclusions: The outcome of lung resection of metastases from CRC in our hospital was satisfactory. Aggressive lung resection for cases even after liver resection and repeated pulmonary recurrence may improve long-term outcomes.Vascular invasion of primary tumor and the pre-operative serum CEA and CA 19-9 level can be predictive markers for recurrence.
Abstract P2-14-06: Withdrawn
Authors: I Athanasiou, MW Reed, A Shrestha, K-L Cheung, R Audisio, K Collins, L Wyld
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Athanasiou I, Reed MW, Shrestha A, Cheung K-L, Audisio R, Collins K, Wyld L. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-06.
Antibiotics for Ceftriaxone-Resistant Gram-Negative Bacterial Bloodstream Infections
Authors: Renaud Prevel, Driss Berdaï, Alexandre Boyer
Journal: JAMA (2019)

To the Editor Dr Harris and colleagues conducted a well-designed study investigating whether carbapenems for extended-spectrum β-lactamase–producing enterobacteria could be spared.1 The results should be interpreted with caution.
Comprehensive molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon.
Authors: Alberto Puccini, Kelsey Poorman, Mohamed E. Salem, Richard M. Goldberg, Anthony Frank Shields, Martin D Berger, Francesca Battaglin, Ryuma Tokunaga, Madiha Naseem, Wu Zhang, Shivani Soni, W. Michael Korn, Philip Agop Philip, John Marshall, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2019)

63 Background: Signet ring cell carcinoma (SRCC) is a rare variant of adenocarcinoma, accounting for about 10% of gastric cancer (GC) and 1% of colorectal cancer (CRC). SRCC is associated with poor prognosis, however little is known about the underlying molecular characteristics. Herein, we aimed to characterize the molecular features of SRCCs, and to compare the molecular profile of SRCC to adenocarcinoma; further, we assessed the impact of tumor location on the molecular profile of SRCC. Methods: SRCCs were analyzed using NGS (MiSeq on 47 genes, NextSeq on 592 genes), immunohistochemistry, and in-situ hybridization. Tumor mutational burden (TMB) was calculated based on somatic nonsynonymous missense mutations, and microsatellite instability (MSI) was evaluated by NGS of known MSI loci. Chi-square and t-tests were used for comparative analyses. Results: A total of 8,500 CRC and 1,100 GC were screened for SRCC histology. Seventy-six SRCC were identified from the CRC cohort (&lt;1%) and 98 from the GC cohort (9%). The most frequently mutated genes in CRC-SRCC were TP53 (47%), ARID1A (26%), APC (25%), KRAS (22%), RFN43 (16%), KMT2D (12%), KMT2C (11%), SMAD4 (10%) and BRAF (10%), while in GC-SRCC were TP53 (42%), ARID1A (27%), CDH1 (11%), BAP1 (7%), PIK3CA (7%), ERBB2 (5%). When compared to non-SRCC histology (N=3522), CRC-SRCC (N=37) showed more frequently mutation in BRCA1 (11% vs 1%, P &lt; .001) and less mutation in APC (19% vs 78%, P &lt; .001), KRAS (22% vs 51%, P = .001) and TP53 (47% vs 73%, P = .001). Among GC cohort, SRCC (N=54) had a higher frequency of mutations in CDH1, BAP1, and ERBB2, and higher rate of amplification MYB compared to non-SRCC (N=540), although none of these differences were statistically significance. When we compared GC-SRCC vs. CRC-SRCC, only the mutation rate in APC (0% vs 25%) and KRAS (2% vs 22%) genes were significantly different (P &lt; .001). Conclusions: Our research is the first to comprehensively characterize the molecular features of SRCC. Our data suggest that SRCCs harbor similar molecular profile, regardless the tumor location. On the other hand, significant differences were observed between SRCCs and non-SRCC tumors, therefore tailored therapy should be provided to these patients.
DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-XL for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax
Authors: Sajid Khan, Xuan Zhang, Dongwen Lv, Yonghan He, Peiyi Zhang, Xingui Liu, Dinesh Thummuri, Qi Zhang, Marina Y. Konopleva, Robert A. Hromas, Guangrong Zheng, Daohong Zhou
Journal: Blood (2018)
Responsibility and Sustainability in Brain Science, Technology, and Neuroethics in China—a Culture-Oriented Perspective
Authors: Yi Wang, Jie Yin, Guoyu Wang, Pingping Li, Guoqiang Bi, Suning Li, Xiaohuan Xia, Jianren Song, Gang Pei, Jialin C. Zheng
Journal: Neuron (2019)
Fitness and Body Mass Index During Adolescence and Disability Later in Life
Authors: Pontus Henriksson, Hanna Henriksson, Per Tynelius, Daniel Berglind, Marie Löf, I-Min Lee, Eric J. Shiroma, Francisco B. Ortega
Journal: Annals of Internal Medicine (2019)

Background: Low physical fitness, obesity, and the combination of the two in adolescence may be related to risk for disability in adulthood, but this has rarely been studied. Objective: To examine individual and combined associations of cardiorespiratory fitness and obesity in male adolescents with later receipt of a disability pension due to all and specific causes. Design: Population-based cohort study. Setting: Sweden. Participants: 1 079 128 Swedish adolescents aged 16 to 19 years who were conscripted into the military between 1972 and 1994. Measurements: Cardiorespiratory fitness and body mass index (BMI) were measured at conscription and were related to information on later receipt of a disability pension obtained from the Social Insurance Agency. Results: Over a median follow-up of 28.3 years, 54 304 men were granted a disability pension. Low cardiorespiratory fitness was strongly associated with later receipt of a disability pension due to all causes (hazard ratio, 3.74 [95% CI, 3.55 to 3.95] for lowest vs. highest fitness decile) and specific causes (psychiatric, musculoskeletal, injuries, nervous system, circulatory, and tumors). Obesity was associated with greater risk for receipt of a disability pension due to all and specific causes, with the greatest risks observed for class II and III obesity. Compared with being unfit, being moderately or highly fit was associated with attenuated risk for receipt of a disability pension across BMI categories. Limitation: The cohort did not include women, had data on smoking and alcohol intake only in a subsample, and lacked repeated measures of exposures and covariates. Conclusion: Low cardiorespiratory fitness, obesity, and the combination of the two were strongly associated with later chronic disability due to a wide range of diseases and causes. Although additional well-designed studies are required, these findings support the importance of high cardiorespiratory fitness and healthy body weight during adolescence to prevent later chronic disease. Primary Funding Source: Karolinska Institutet.
The PKC binding protein gene NELL1 and the T-cell differentiation protein gene MAL are hypermethylated in gastric cancer
Authors: Yuriko Mori, Yulan Cheng, Alexandru Olaru, Bogdan Paun, Zhe Jin, Fumiaki Sato, Takatsugu Kan, Tetsuo Ito, Stefan David, Rachana Agarwal, James Hamilton, John Abraham, Stephen Meltzer
Journal: Cancer Research (2007)

1134  Background and Aim: Promoter hypermethylation is an important molecular event in human cancers that is associated with transcriptional inactivation of multiple tumor suppressor genes. In order to detect novel candidate tumor suppressor genes, we previously conducted a genome-wide search for novel hypermethylation targets in colon cancers. In this search, we found two novel methylation target genes: the protein kinase C binding protein gene NELL1 and the T-cell differentiation protein gene MAL. NELL1 and MAL were reported to be involved in the process of cell differentiation and growth suppression in bone and lymphocyte, respectively. However, their involvement in digestive tract malignancies has never been studied. In the current study, we investigated the epigenetic abnormality of NELL1 and MAL in gastric cancer.  Methods: Forty-seven primary gastric tumors and 41 normal gastric mucosae were analyzed for NELL1 and MAL promoter methylation status. The methylation status was assessed using the real-time quantitative methylation specific PCR (MSP) method. The association of promoter hypermethylation and mRNA downregulation was evaluated in gastric cancer cell lines that underwent 5-aza-deoxycitidine induced global genomic DNA demethylation using the real-time quantitative RT-PCR and MSP methods.  Results: NELL1 and MAL demonstrated promoter methylation in 10 of 47 (21%) primary gastric cancers. On the other hand, NELL1 and MAL were methylated in none and only one of 41 normal gastric mucosae, respectively. We also confirmed that the levels of promoter methylation and mRNA expression are inversely associated in 5-aza-deoxycitidien treated gastric cancer cell lines. No significant association was observed between promoter methylation status in tissues and age, gender, tumor stage, or histological subtype for either NELL1 or MAL. Interestingly, NELL1 methylation was significantly more frequent in microsatellite-unstable (MSI-H) cancers (4 of 7) than in microsatelite-stable cancers (6 of 40; p  Conclusion: Our data demonstrate that both NELL1 and MAL are abnormally inactivated via promoter methylation in a subset of human gastric cancers. This abnormal methylation appears to occur in an early stage of gastric carcinogenesis because their methylation prevalence is independent of tumor stage. Considering their known biological roles in other organs, methylation-mediated inactivation of these two genes is likely to play a role in genesis and/or progression of a subset of gastric cancer.
Environmental Cell-Matrix Adhesion Modulates Pluripotent Stem Cell Fate Toward Definitive Hemogenic Endothelium and Hematopoietic Progenitor Cells
Authors: Akinori Yuzuriha, Sou Nakamura, Toshie Kusunoki, Takuya Matsumoto, Naoshi Sugimoto, Kiyotoshi Sekiguchi, Koji Eto
Journal: Blood (2018)
David Tovey replies to Melanie Newman and <i>The BMJ</i>
Authors: David Tovey
Journal: BMJ (2019)

Newman asks whether Cochrane has “lost its way” given recent ructions arising from the governing board’s decision to remove membership status from Peter Gotzsche.1 On the contrary, by all objective measures, Cochrane is thriving.

Feel free to ignore the evidence of sustained income growth that Newman cites. Look instead at the continuing international spread of Cochrane’s networks, increasing its reach in South America, eastern Europe, and South East Asia and initiating new networks in China and the United States. Look also at the expanding work on multi-language content development and the doubling in access to review summaries on the Cochrane website over the past 12 months, dominated by people from non-anglophone countries. In terms of impact, the use of …
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
Authors: Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer, Roland Goldbrunner, Oliver Schnell, Oliver Bähr, Martin Uhl, Clemens Seidel, Ghazaleh Tabatabai, Thomas Kowalski, Florian Ringel, Friederike Schmidt-Graf, Bogdana Suchorska, Stefanie Brehmer, Astrid Weyerbrock, Miriam Renovanz, Lars Bullinger, Norbert Galldiks, Peter Vajkoczy, Martin Misch, Hartmut Vatter, Moritz Stuplich, Niklas Schäfer, Sied Kebir, Johannes Weller, Christina Schaub, Walter Stummer, Jörg-Christian Tonn, Matthias Simon, Vera C Keil, Michael Nelles, Horst Urbach, Martin Coenen, Wolfgang Wick, Michael Weller, Rolf Fimmers, Matthias Schmid, Elke Hattingen, Torsten Pietsch, Christoph Coch, Martin Glas
Journal: The Lancet (2019)
Diagnosis of Primary Clear Cell Carcinoma of the Vagina by 18F-FDG PET/CT
Authors: Zhanli Fu, Xueqi Chen, Xing Yang, Qian Li
Journal: Clinical Nuclear Medicine (2019)

A 41-year-old woman presented with irregular vaginal bleeding, and a vaginal tumor was found and proved to be a clear cell carcinoma by biopsy. An F-FDG PET/CT was performed to exclude its metastatic possibility, which showed the vaginal tumor was the only lesion with F-FDG avidity. The vaginectomy and hysterectomy were performed to resect the lesion, and primary clear cell carcinoma of the vagina was finally diagnosed.
Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator‐Activated Receptor γ in Mice
Authors: Jingjing Tong, Cui‐Juan Han, Jia‐Zhen Zhang, Wen‐Zhi He, Guo‐Jun Zhao, Xu Cheng, Lei Zhang, Ke‐Qiong Deng, Ye Liu, Hui‐Fen Fan, Song Tian, Jingjing Cai, Zan Huang, Zhi‐Gang She, Peng Zhang, Hongliang Li
Journal: Hepatology (2019)

Nonalcoholic fatty liver disease (NAFLD) has become a worldwide epidemic. A large and growing unmet therapeutic need has inspired numerous studies in the field. Integrating the published genomic data available in the Gene Expression Omnibus (GEO) with NAFLD samples from rodents, we discovered that interferon regulatory factor 6 (IRF6) is significantly downregulated in high‐fat diet (HFD)‐induced fatty liver. In the current study, we identified IRF6 in hepatocytes as a protective factor in liver steatosis (LS). During HFD challenge, hepatic Irf6 was suppressed by promoter hypermethylation. Severity of HFD‐induced LS was exacerbated in hepatocyte‐specific Irf6 knockout mice, whereas hepatocyte‐specific transgenic mice overexpressing Irf6 (IRF6‐HTG) exhibited alleviated steatosis and metabolic disorder in response to HFD feeding. Mechanistic studies in vitro demonstrated that hepatocyte IRF6 directly binds to the promoter of the peroxisome proliferator‐activated receptor γ (PPARγ) gene and subsequently halts the transcription of Pparγ and its target genes (e.g., genes that regulate lipogenesis and lipid acid uptake) under physiological conditions. Conclusion : Irf6 is downregulated by promoter hypermethylation upon metabolic stimulus exposure, which fail to inhibit Pparγ and its targets, driving abnormalities of lipid metabolism.
Abstract P2-06-13: A novel small molecule JMX0293 inhibits the growth of triple-negative breast cancer via suppressing STAT3 and inducing apoptosis
Authors: J Dong, J Xu, H Kim, J Zhou, Q Shen
Journal: Cancer Research (2019)

Abstract Approximately 30-40% of breast cancer cases are estrogen receptor negative (ENBC), including the most aggressive triple-negative subtype (TNBC) which spread early and recur frequently with a poor prognosis. ENBCs do not respond to selective ER modulators such as tamoxifen or aromatase inhibitors, and therefore, there is an urgent need of non-ER-based therapies for ENBC and TNBC. We recently developed a novel small molecule JMX0293 based on our lead drug candidate HJC0152. Both HJC0152 and JMX0293 were able to suppress cell proliferation of both ER+ (MCF-7, T-47D) and ER- (MDA-MB-231 and MDA-MB-468) breast cancer cell lines in a dose-dependent manner, with significantly lower toxicity against normal mammary epithelial cells (MCF-10A) in vitro. JMX0293 exhibited moderately improved anti-proliferative effects against highly invasive TNBC cell line MDA-MB-231 and ER+ breast cancer cell line MCF-7 with IC50 values of 0.92 and 2.24 μM, respectively. JMX0293 was also demonstrated to induce apoptosis of MDA-MB-231 cells dose-dependently. Mechanistically, JMX0293 inhibited STAT3 phosphorylation at Tyr705 residue, leading to the down-regulation of Bcl-2 and upregulation of apoptotic proteins including Bax, cleaved-caspase 3 and cleaved-PARP. In addition, JMX0293 reduced the ratio of Bcl-2 to Bax. In vivo, JMX0293 treatment for 2 weeks at a dose of 10 mg/kg significantly suppressed the growth of TNBC xenograft tumors in mice with minimal impact on general health and body weight. Our results suggest that JMX0293 induces TNBC cell apoptosis and contributes to its anti-proliferative effect through inhibiting transcription factor STAT3, and JMX0293 could be further characterized and optimized for developing a promising therapeutic for treating ENBC and TNBC. This work was supported by grant (R01 CA231150) from the NIH/NCI. Citation Format: Dong J, Xu J, Kim H, Zhou J, Shen Q. A novel small molecule JMX0293 inhibits the growth of triple-negative breast cancer via suppressing STAT3 and inducing apoptosis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-06-13.
Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289)
Authors: Roni Shouval, Ilan Youngster, Mika Geva, Adi Eshel, Ivetta Danylesko, Avichai Shimoni, Katia Beider, Joshua A Fein, Itai Sharon, Omry Koren, Arnon Nagler
Journal: Blood (2018)